We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+97.38%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$766M
AUM Growth
+$277M
Cap. Flow
-$10.8M
Cap. Flow %
-1.41%
Top 10 Hldgs %
89.44%
Holding
31
New
2
Increased
2
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$12.7M
2
AQST icon
Aquestive Therapeutics
AQST
+$10.8M
3
ABVX
Abivax
ABVX
+$4.62M
4
VTVT icon
vTv Therapeutics
VTVT
+$2.94M

Top Sells

Rank Stock Value
1
CRGX
CARGO Therapeutics
CRGX
+$18.2M
2
UPB
Upstream Bio Inc
UPB
+$7.47M
3
PVLA
Palvella Therapeutics
PVLA
+$5.8M
4
AURA icon
Aura Biosciences
AURA
+$2.71M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$1.87M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLYS icon
1
Mineralys Therapeutics
MLYS
$2.35B
$237M 31.01%
6,263,151
+588,235
+10% +$12.7M
SRRK icon
2
Scholar Rock
SRRK
$5.71B
$209M 27.29%
5,612,896
– –
KLRS
3
Kalaris Therapeutics
KLRS
$88.7M
$66.2M 8.64%
11,448,081
– –
SEPN
4
Septerna Inc
SEPN
$1.49B
$59.2M 7.73%
3,149,128
– –
NGNE icon
5
Neurogene
NGNE
$696M
$29.8M 3.89%
1,717,127
– –
ALMS
6
Alumis Inc
ALMS
$3.57B
$19.2M 2.5%
4,801,370
– –
UPB
7
Upstream Bio Inc
UPB
$349M
$18.1M 2.36%
962,154
-481,077
-33% -$7.47M
GOSS icon
8
Gossamer Bio
GOSS
$66.5M
$16.1M 2.11%
6,130,268
– –
LENZ
9
LENZ Therapeutics
LENZ
$172M
$16M 2.09%
343,012
– –
AQST icon
10
Aquestive Therapeutics
AQST
$462M
$14M 1.82%
+2,500,000
New +$10.8M
PVLA
11
Palvella Therapeutics
PVLA
$1.98B
$13.1M 1.72%
209,634
-130,109
-38% -$5.8M
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
$10.3M 1.35%
675,504
– –
VTVT icon
13
vTv Therapeutics
VTVT
$121M
$8.74M 1.14%
374,461
+167,677
+81% +$2.94M
NKTX icon
14
Nkarta
NKTX
$162M
$7.8M 1.02%
3,768,035
– –
CTNM
15
Contineum Therapeutics
CTNM
$526M
$6.71M 0.88%
571,142
-17,674
-3% -$142K
ACLX
16
DELISTED
Arcellx
ACLX
$6.66M 0.87%
81,165
-20,292
-20% -$1.46M
ABVX
17
Abivax
ABVX
$11B
$6.41M 0.84%
+75,442
New +$4.62M
JBIO
18
Jade Biosciences
JBIO
$1.22B
$4.58M 0.6%
531,163
– –
AURA icon
19
Aura Biosciences
AURA
$729M
$3.61M 0.47%
584,849
-415,151
-42% -$2.71M
ZYME icon
20
Zymeworks
ZYME
$1.68B
$3.55M 0.46%
207,901
-102,399
-33% -$1.47M
SRZN icon
21
Surrozen
SRZN
$229M
$3.11M 0.41%
241,400
– –
RYTM icon
22
Rhythm Pharmaceuticals
RYTM
$7B
$3.06M 0.4%
30,285
-20,191
-40% -$1.87M
STRO icon
23
Sutro Biopharma
STRO
$379M
$1.91M 0.25%
219,681
– –
TERN
24
DELISTED
Terns Pharmaceuticals
TERN
$1.02M 0.13%
135,573
-66,775
-33% -$426K
BOLT icon
25
Bolt Biotherapeutics
BOLT
$7.36M
$260K 0.03%
48,830
-3,626
-7% -$20.1K
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q3 2025 Portfolio in Review

As of Q3 2025, Samsara BioCapital held 31 positions worth $766M, up 57% from $489M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Samsara BioCapital's Q3 2025 filing shows 2 new, 2 increased, 9 reduced and 4 closed positions. Its largest new stake was Aquestive Therapeutics: 2,500,000 shares worth $14M. The largest sale was CARGO Therapeutics, an estimated $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Samsara BioCapital's largest Q3 2025 buy was Aquestive Therapeutics: 2,500,000 shares worth $14M.
  • Samsara BioCapital added most to Mineralys Therapeutics in Q3 2025, an estimated $12.7M increase.
  • Samsara BioCapital's biggest Q3 2025 reduction was Upstream Bio Inc, cutting an estimated $7.47M.
  • Samsara BioCapital fully exited CARGO Therapeutics in Q3 2025, selling an estimated $18.2M.
  • Samsara BioCapital's ten largest holdings make up 89% of its $766M portfolio in Q3 2025.
  • Samsara BioCapital opened 2 new positions and closed 4 in Q3 2025.
  • Samsara BioCapital's portfolio value rose 57% quarter-over-quarter to $766M.

Based on Samsara BioCapital's 13F filing for Q3 2025, filed 14 Nov 2025.